First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

PURPOSE: Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. This Phase I trial evaluated this ADC as a potential therapeutic for pretreated pati...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Starodub, Alexander N., Ocean, Allyson J., Shah, Manish A., Guarino, Michael J., Picozzi, Jr., Vincent J., Vahdat, Linda T., Thomas, Sajeve S., Govindan, Serengulam V., Maliakal, Pius P., Wegener, William A., Hamburger, Steven A., Sharkey, Robert M., Goldenberg, David M.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4558321/
https://ncbi.nlm.nih.gov/pubmed/25944802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3321
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki